Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management

Ferdinando D'Amico, Daniel C Baumgart, Silvio Danese, Laurent Peyrin-Biroulet, Ferdinando D'Amico, Daniel C Baumgart, Silvio Danese, Laurent Peyrin-Biroulet

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19) pandemic is a worldwide emergency. An increasing number of diarrhea cases is reported. Here we investigate the epidemiology, clinical presentation, molecular mechanisms, management, and prevention of SARS-CoV-2 associated diarrhea. We searched on PubMed, EMBASE, and Web of Science up to March 2020 to identify studies documenting diarrhea and mechanism of intestinal inflammation in patients with confirmed diagnosis of SARS-CoV-2 infection. Clinical studies show an incidence rate of diarrhea ranging from 2% to 50% of cases. It may precede or trail respiratory symptoms. A pooled analysis revealed an overall percentage of diarrhea onset of 10.4%. SARS-CoV uses the angiotensin-converting enzyme 2 (ACE2) and the serine protease TMPRSS2 for S protein priming. ACE2 and TMPRSS2 are not only expressed in lung, but also in the small intestinal epithelia. ACE2 is expressed furthermore in the upper esophagus, liver, and colon. SARS-CoV-2 binding affinity to ACE2 is significantly higher (10-20 times) compared with SARS-CoV. Several reports indicate viral RNA shedding in stool detectable longer time period than in nasopharyngeal swabs. Current treatment is supportive, but several options appear promising and are the subject of investigation. Diarrhea is a frequent presenting symptom in patients infected with SARS-CoV-2. Increasing evidence indicates possible fecal oral transmission, indicating the need for a rapid and effective modification of the screening and diagnostic algorithms. The optimal methods to prevent, manage, and treat diarrhea in COVID-19 infected patients are subjects of intensive research.

Keywords: ACE2; Angiotensin-Converting Enzyme 2; COVID-19; Diarrhea; Epidemiology; SARS-CoV-2; TMPRSS2.

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Proposed model for SARS-CoV-2-associated diarrhea. SARS-CoV uses ACE2 and the serine protease TMPRSS2 for entry in lung AT cells. ACE2 and TMPRSS2 are not only expressed in lung, but also the small intestinal epithelia. ACE2 is expressed in the upper esophagus, liver, and colon. ACE2 is also necessary for the surface expression of amino acid transporters of the small intestine. Amino acids, like tryptophan, regulate the secretion of antimicrobial peptides by Paneth cells via mTOR pathway activation. Antimicrobial peptides impact the composition and diversity of the microbiota. Disturbance of this pathway could drive inflammation (enteritis) and ultimately diarrhea. SARS-CoV-2 rendering courtesy of Centers for Disease Control and Prevention. The science cartoon was created with Servier Medical Art licensed under a Creative Commons Attribution 3.0 Unported License. AT, Alveolar Type; mTOR, mammalian target of rapamycin.

References

    1. Zhu N., Zhang D., Wang W. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
    1. Wu F., Zhao S., Yu B. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
    1. Lu R., Zhao X., Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.
    1. Gu J., Han B., Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. [published online ahead of print, 2020 Mar 3] Gastroenterology. 2020:S0016–S5085. (20)30281-X. doi:10.1053/j.gastro.2020.02.054.
    1. Doremalen N van, Bushmaker T., Morris D.H. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–1567.
    1. Anon WHO Director-General’s opening remarks at the media briefing on COVID-19: 11 March 2020. Available at:
    1. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. [published online ahead of print, 2020 Feb 7] JAMA. 2020 doi: 10.1001/jama.2020.1585.
    1. Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
    1. Pan L., Mu M., Ren H.G. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. PracticeUpdate. Available at:
    1. Chan J.F.-W., Yuan S., Kok K.-H. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
    1. Fan Y., Zhao K., Shi Z.-L. Bat coronaviruses in China. Viruses. 2019;11:210.
    1. Song Z., Xu Y., Bao L. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11:59.
    1. Cui J., Li F., Shi Z.-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192.
    1. Guo Y.-R., Cao Q.-D., Hong Z.-S. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: an update on the status. Mil Med Res. 2020;7:11.
    1. Zhou P., Yang X.-L., Wang X.-G. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
    1. Hoffmann M., Kleine-Weber H., Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. [published online ahead of print, 2020 Mar 4] Cell. 2020 S0092-8674(20)30229-4. doi:10.1016/j.cell.2020.02.052.
    1. Wan Y., Shang J., Graham R. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94 e00127-20.
    1. Wrapp D., Wang N., Corbett K.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
    1. Zhang H., Kang Z., Gong H. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020:2020. 01.30.927806.
    1. Kawase M., Shirato K., van der Hoek L. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86:6537–6545.
    1. Hashimoto T., Perlot T., Rehman A. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477–481.
    1. Gao Q.Y., Chen Y.X., Fang J.Y. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21:125–126.
    1. Guan W.J., Ni Z.Y., Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
    1. Xu X.-W., Wu X.-X., Jiang X.-G. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
    1. Wu W.S., Li Y.G., Wei Z.F. [Investigation and analysis on characteristics of a cluster of COVID-19 associated with exposure in a department store in Tianjin] Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:489–493.
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Xiao F., Tang M., Zheng X. Evidence for gastrointestinal infection of SARS-CoV-2. [published online ahead of print, 2020 Mar 3] Gastroenterology. 2020 S0016-5085(20)30282-1. doi:10.1053/j.gastro.2020.02.055.
    1. Hosoda T., Sakamoto M., Shimizu H. SARS-CoV-2 enterocolitis with persisting to excrete the virus for about two weeks after recovering from diarrhea: a case report. [published online ahead of print, 2020 Mar 19] Infect Control Hosp Epidemiol. 2020:1–4. doi: 10.1017/ice.2020.87.
    1. Young B.E., Ong S.W.X., Kalimuddin S. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. [published online ahead of print, 2020 Mar 3] JAMA. 2020 doi: 10.1001/jama.2020.3204.
    1. Ding Q., Lu P., Fan Y. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China. [published online ahead of print, 2020 Mar 20] J Med Virol. 2020 10.1002/jmv.25781. doi:10.1002/jmv.25781.
    1. Liu M., He P., Liu H.G. [Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia] Zhonghua Jie He Hu Xi Za Zhi. 2020;43:209–214.
    1. Luo S, Zhang X, Xu H. Don’t overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clinical Gastroenterology and Hepatology. Available at: 10.1016/j.cgh.2020.03.043. Accessed March 23, 2020.
    1. Lu X., Zhang L., Du H. SARS-CoV-2 infection in children. N Engl J Med. 2020;382:1663–1665.
    1. Li L.-Q., Huang T., Wang Y.-Q. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Mar 12 doi: 10.1002/jmv.25757. [Epub ahead of print]
    1. Jin X., Lian J.-S., Hu J.-H. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. [published online ahead of print, 2020 Mar 24] Gut. 2020 gutjnl-2020-320926. doi:10.1136/gutjnl-2020-320926.
    1. Song Y., Liu P., Shi X.L. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. [published online ahead of print, 2020 Mar 5] Gut. 2020 gutjnl-2020-320891. doi:10.1136/gutjnl-2020-320891.
    1. Holshue M.L., DeBolt C., Lindquist S. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936.
    1. Mo P., Xing Y., Xiao Y. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. [published online ahead of print, 2020 Mar 16] Clin Infect Dis. 2020 ciaa270. doi:10.1093/cid/ciaa270.
    1. Leung W.K., To K.-F., Chan P.K.S. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125:1011–1017.
    1. Booth C.M., Matukas L.M., Tomlinson G.A. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809.
    1. Peiris J.S.M., Chu C.M., Cheng V.C.C. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–1772.
    1. Assiri A., Al-Tawfiq J.A., Al-Rabeeah A.A. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752–761.
    1. Choi W.S., Kang C.-I., Kim Y. Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea. Infect Chemother. 2016;48:118–126.
    1. Garbati M.A., Fagbo S.F., Fang V.J. A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes. PLoS One. 2016;11
    1. Ungaro R.C., Sullivan T., Colombel J.-F. What should gastroenterologists and patients know about COVID-19? [published online ahead of print, 2020 Mar 17] Clin Gastroenterol Hepatol. 2020 S1542-3565(20)30330-X. doi:10.1016/j.cgh.2020.03.020.
    1. Repici A., Maselli R., Colombo M. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know. [published online ahead of print, 2020 Mar 14] Gastrointest Endosc. 2020 S0016-5107(20)30245-5. doi:10.1016/j.gie.2020.03.019.
    1. Ianiro G., Mullish B.H., Kelly C.R. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020;5:430–432.
    1. Ferrario C.M., Jessup J., Chappell M.C. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–2610.
    1. Diaz J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. [published online ahead of print, 2020 Mar 18] J Travel Med. 2020 taaa041. doi: 10.1093/jtm/taaa041.
    1. Avery M.E., Snyder J.D. Oral therapy for acute diarrhea. The underused simple solution. N Engl J Med. 1990;323:891–894.
    1. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334–339.
    1. Logan C., Beadsworth M.B.J., Beeching N.J. HIV and diarrhoea: what is new? Curr Opin Infect Dis. 2016;29:486–494.
    1. Bradley K.C., Finsterbusch K., Schnepf D. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep. 2019;28:245–256.
    1. Tian X., Li C., Huang A. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9:382–385.
    1. Cao B., Wang Y., Wen D. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799.
    1. Wang M., Cao R., Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.
    1. Yao X., Ye F., Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [published online ahead of print, 2020 Mar 9] Clin Infect Dis. 2020:ciaa237. doi: 10.1093/cid/ciaa237.
    1. Kapoor K.M., Kapoor A. Role of chloroquine and hydroxychloroquine in the treatment of COVID-19 infection: a systematic literature review. medRxiv. 2020:2020. 03.24.20042366.
    1. Anon Drugs@FDA: FDA-approved drugs. Available at:
    1. Richardson P., Griffin I., Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31.
    1. Liang W., Feng Z., Rao S. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. [published online ahead of print, 2020 Feb 26] Gut. 2020 gutjnl-2020-320832. doi:10.1136/gutjnl-2020-320832.
    1. Anon Diarrhoeal disease. Available at:
    1. Qiu H.J., Yuan L.X., Huang X.K. [Using the big data ofinternet to understand coronavirus disease 2019’s symptom characteristics: a big data study] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020;55:E004.
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24 doi: 10.1001/jama.2020. 2648. [Epub ahead of print]
    1. Li R., Pei S., Chen B. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). [published online ahead of print, 2020 Mar 16] Science. 2020:eabb3221. doi: 10.1126/science.abb3221.
    1. Meo S.A., Alhowikan A.M., Al-Khlaiwi T. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24:2012–2019.
    1. Yeo C., Kaushal S., Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020;5:335–337.
    1. Spiteri G., Fielding J., Diercke M. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25:2000178.
    1. Lescure F.-X., Bouadma L., Nguyen D. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious Diseases 2020;0. Available at:
    1. Chang D., Lin M., Wei L. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323:1092–1093.
    1. Wang Z., Chen X., Lu Y. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14:64–68.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner